Diabetes reversed in rats in latest research
The latest research on Persista Bio’s technology, implanting cells in vivo without immunosuppression, is now available via preprint on bioRxiv. The study shows the reversal of diabetes in rats. Researchers used a macroencapsulation system that enabled effective and practical therapy by providing the cells oxygenation and allowing high density of cells in the capsule. In this study, the […]
Persista Bio CEO to present at Meeting on the Mesa
IPITA Conference to include a presentation by Dr. Minglin Ma
Dr. Minglin Ma is a co-author on a newly published review of diabetes cell therapies
https://pubmed.ncbi.nlm.nih.gov/39227741 This review article describes current, developing and future cell replacement therapy options, touching on animal models and the regulatory environment.